These findings impact the current 5th WHO Classification (WHO-2022) [15], 2022 ELN recommendations (ELN-2022) [16] and International Consensus Classification (ICC) [17], resulting in the changing of the category, “AML with biallelic mutations of CEBPA” into “AML with in-frame bZIP mutations of CEBPA.” However, the 5-year event-free survival (EFS) was less than 50% [4], and the cumulative incidence of relapse was approaching 40% in this category [18]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.